Integrin αvβ6-Targeted SPECT Imaging for Pancreatic Cancer Detection

被引:47
|
作者
Liu, Zhaofei [1 ,2 ]
Liu, Hao [1 ,2 ]
Ma, Teng [1 ,2 ]
Sun, Xianlei [1 ,2 ]
Shi, Jiyun [1 ]
Jia, Bing [1 ,2 ]
Sun, Yi [3 ]
Zhan, Jun [4 ,5 ]
Zhang, Hongquan [4 ,5 ]
Zhu, Zhaohui [3 ]
Wang, Fan [1 ,2 ,6 ]
机构
[1] Peking Univ, Med Isotopes Res Ctr, Beijing 100191, Peoples R China
[2] Peking Univ, Sch Basic Med Sci, Dept Radiat Med, Beijing 100191, Peoples R China
[3] Peking Union Med Coll Hosp, Dept Nucl Med, Beijing, Peoples R China
[4] Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
[5] Peking Univ, Hlth Sci Ctr, Dept Anat Histol & Embryol, Lab Mol Cell Biol & Tumor Biol, Beijing 100191, Peoples R China
[6] Chinese Acad Sci, Inst Biophys, Interdisciplinary Lab, Beijing 100080, Peoples R China
基金
北京市自然科学基金; 中国国家自然科学基金;
关键词
pancreatic cancer; molecular imaging; integrin alpha(v)beta(6); phage display; SPECT/CT; CYSTINE KNOT PEPTIDES; IN-VIVO; ALPHA-V-BETA-6; INTEGRIN; INTEGRIN-ALPHA(V)BETA(6); EXPRESSION; GENERATION; CELLS;
D O I
10.2967/jnumed.113.132969
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
lntegrin alpha(v)beta(6), a member of the integrin family, is specifically expressed in many malignancies but not in normal organs. Overexpression of integrin alpha(v)beta(6) is usually correlated with malignant potential and poor prognosis. In this study, we describe the synthesis and evaluation of a Tc-99m-labeled integrin alpha(v)beta(6)-targeting peptide as a SPECT radiotracer for the in vivo imaging of integrin alpha(v)beta(6) expression. Methods: An integrin alpha(v)beta(6)-targeting peptide (denoted as the HK peptide) was conjugated with 6-hydrazinonicotinyl (HYNIC) and radiolabeled with Tc-99m using tricine and TPPTS (trisodium triphenylphosphine-3,3',3 '' trisulfonate) as coligands. The in vitro and in vivo characteristics of Tc-99m-HYNIC(tricine)(TPPTS)-HK (Tc-99m-HHK) were investigated in BxPC-3 (integrin alpha(v)beta(6)-positive) and HEK293 (integrin alpha(v)beta(6)-negative) models. The ability of Tc-99m-HHK to detect liver metastasis of pancreatic cancer was evaluated using small-animal SPEC/CT. Results: Tc-99m-HHK showed high integrin alpha(v)beta(6)-binding specificity both in vitro and in vivo. Tc-99m-HHK was cleared rapidly from the blood and normal organs except for the kidneys. The highest uptake (0.88 +/- 0.12 percentage injected dose per gram) of Tc-99m-HHK in BxPC-3 tumors was observed at 0.5 h after injection. High-contrast images of integrin alpha(v)beta(6)-positive tumors were obtained using Tc-99m-HHK. The minimum nonspecific activity accumulation in normal liver tissues rendered high-quality SPECT/CT images of metastatic lesions. Conclusion: Tc-99m-HHK is a promising SPECT radiotracer for the noninvasive imaging of integrin alpha(v)beta(6) expression in vivo. SPECT/ CT with Tc-99m-HHK could provide an effective approach for the noninvasive detection of primary and metastatic lesions of integrin alpha(v)beta(6)-positive tumors. a
引用
收藏
页码:989 / 994
页数:6
相关论文
共 50 条
  • [1] Integrin αvβ6-targeted MR molecular imaging of breast cancer in a xenograft mouse model
    Li, Dengfeng
    Dong, Chengyan
    Ma, Xiaohong
    Zhao, Xinming
    CANCER IMAGING, 2021, 21 (01)
  • [2] A near-infrared phthalocyanine dye-labeled agent for integrin αvβ6-targeted theranostics of pancreatic cancer
    Gao, Duo
    Gao, Liquan
    Zhang, Chenran
    Liu, Hao
    Jia, Bing
    Zhu, Zhaohui
    Wang, Fan
    Liu, Zhaofei
    BIOMATERIALS, 2015, 53 : 229 - 238
  • [3] First-in-human pilot study of an integrin α6-targeted radiotracer for SPECT imaging of breast cancer
    Gao, Shi
    Jia, Bing
    Feng, Guokai
    Dong, Chengyan
    Du, Hui
    Bai, Lin
    Zhong, Qian
    Ma, Qingjie
    Zeng, Musheng
    Wang, Fan
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)
  • [4] Automated Synthesis and Preclinical Evaluation of Optimized Integrin α6-Targeted Positron Emission Tomography Imaging of Pancreatic Cancer
    Chen, Liping
    Fu, Haitian
    He, Huihui
    Lou, Kequan
    Li, Qingbo
    Ye, Jiacong
    Feng, Guokai
    Yu, Chunjing
    MOLECULAR PHARMACEUTICS, 2023, 20 (08) : 4277 - 4284
  • [5] Integrin αvβ6-targeted MR molecular imaging of breast cancer in a xenograft mouse model
    Dengfeng Li
    Chengyan Dong
    Xiaohong Ma
    Xinming Zhao
    Cancer Imaging, 21
  • [6] The Effect of Bi-Terminal PEGylation of an Integrin αvβ6-Targeted 18F Peptide on Pharmacokinetics and Tumor Uptake
    Hausner, Sven H.
    Bauer, Nadine
    Hu, Lina Y.
    Knight, Leah M.
    Sutcliffe, Julie L.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (05) : 784 - 790
  • [7] Integrin α6-Targeted Magnetic Resonance Imaging of Hepatocellular Carcinoma in Mice
    Zhang, Yun
    Zhao, Jing
    Cai, Jing
    Ye, Jia-Cong
    Xiao, Yi-Tai
    Mei, Yan
    Zeng, Mu-Sheng
    Xie, Chuan-Miao
    Jiang, Yong
    Feng, Guo-Kai
    MOLECULAR IMAGING AND BIOLOGY, 2020, 22 (04) : 864 - 872
  • [8] Integrin α6-Targeted Molecular Imaging of Central Nervous System Leukemia in Mice
    Zhang, Wenbiao
    Li, Yongjiang
    Chen, Guanjun
    Yang, Xiaochun
    Hu, Junfeng
    Zhang, Xiaofei
    Feng, Guokai
    Wang, Hua
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2022, 10
  • [9] Multimodal Molecular Imaging of Integrin αvβ3 for In Vivo Detection of Pancreatic Cancer
    Trajkovic-Arsic, Marija
    Mohajerani, Pouyan
    Sarantopoulos, Athanasios
    Kalideris, Evdokia
    Steiger, Katja
    Esposito, Irene
    Ma, Xiaopeng
    Themelis, George
    Burton, Neal
    Michalski, Christoph W.
    Kleeff, Joerg
    Stangl, Stefan
    Beer, Ambros J.
    Pohle, Karolin
    Wester, Hans-Juergen
    Schmid, Roland M.
    Braren, Rickmer
    Ntziachristos, Vasilis
    Siveke, Jens T.
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (03) : 446 - 451
  • [10] Preclinical Evaluation and First-in-Human Study of [68Ga]Ga-αvβ6-2: A Novel Dimeric Integrin αvβ6-Targeted PET Probe for Pancreatic Cancer Imaging
    Pang, Xiao
    Zhao, Yan
    Chen, Xiaolin
    Zhao, Xinming
    Wang, Mengjiao
    Chen, Xiaoshan
    Yuan, Huiqing
    Sun, Yuhan
    Han, Jingya
    MOLECULAR PHARMACEUTICS, 2025,